Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vobramitamab Tavatecan · MGC026

Antibody-drug conjugate · Cytotoxic, directed at B7-H3 (CD276) · developed by MacroGenics

Phase 1 Most advanced trial
MGNX Developer
1 Registered trials

What is Vobramitamab Tavatecan?

Vobramitamab tavatecan is an antibody-drug conjugate in which a humanized antibody binds B7-H3 (CD276), a protein overexpressed on certain tumor cells, and delivers the topoisomerase I inhibitor exatecan via a cleavable linker. It is being studied in advanced solid tumors, including non-small cell lung cancer, small-cell lung cancer, prostate, bladder, and colorectal cancers, among others.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MGC026
Drug type
Antibody-drug conjugate
Targets
B7-H3 (CD276)
Mechanism
Cytotoxic, directed at B7-H3 (CD276)
Pathways
DNA replication inhibition via topoisomerase I, cell cycle arrest, apoptosis, bystander killing
Therapy area
Oncology
Developer
MacroGenics (MGNX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
6CAR6LS9JU

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06242470 Phase 1 Advanced Solid Tumor Recruiting MGNX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerAdvanced Solid TumorBladder CancerCastration Resistant Prostatic CancerCervical CancerColorectal CancerEndometrial CancerGastric CancerGastro-esophageal CancerMelanomaMetastatic CancerNon Small Cell Lung CancerSarcomaSmall-cell Lung Cancer

Other drugs acting on CD276

More from MacroGenics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the MGNX page.

Follow MGNX, the company behind Vobramitamab Tavatecan

See MGNX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MGNX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.